Altimmune Inc. published a document on a Phase 2b, multicenter, randomized, placebo-controlled trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). The document includes baseline demographics, disease characteristics of study participants, and information on study completion rates and adverse events. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.